通过转录和遗传分析挑战功能性高危多发性骨髓瘤的概念
研究分析Myeloma-XI试验中135例统一治疗、适合移植的多发性骨髓瘤患者,中位随访88个月,早期复发25例(18.5%)。联合IMS/IMWG高危细胞遗传学异常和SKY92基因表达高危特征可识别84%的早期复发,并区分总生存;仅2例(占早期复发8%,占全部1.5%)真正符合功能性高危全部标准。
要点
- 联合IMS/IMWG高危细胞遗传学异常和GEP-HR可识别84%的早期复发。
- 同时具有IMS/IMWG和GEP高危特征者总生存显著短于两者均无者(HR=13.1)。
- 仅2例(1.5%)真正符合功能性高危全部标准,支持更全面的基线诊断分析。
核心结论
- 联合IMS/IMWG高危细胞遗传学异常和SKY92基因表达高危特征可识别大多数早期复发并区分长期结局。
- 真正符合功能性高危全部标准的患者比例很低,支持更全面的基线诊断分析以 upfront 识别早期复发风险。
研究设计与样本
- 分析Myeloma-XI(MyXI)试验中统一治疗、适合移植的多发性骨髓瘤患者135例,中位随访88个月。
- 患者已检测IMS/IMWG定义的高危细胞遗传学异常和SKY92基因表达高危特征。
- 早期复发定义为自体干细胞移植后维持治疗随机化起<18个月内复发。
主要发现
- 25例(18.5%)发生早期复发;其中15例(60%)诊断时为IMS/IMWG高危,8例同时GEP高危。
- 另6例仅GEP高危,会被IMS/IMWG高危遗漏;4例IMS/IMWG和GEP标危者中2例有孤立高危标志,仅2例(占早期复发8%,占全部1.5%)真正符合所有功能性高危标准。
- 联合IMS/IMWG和GEP高危分析识别84%的早期复发。
- 同时具有IMS/IMWG和GEP高危者总生存显著短于两者均无者(HR=13.1;95%CI 6.5-26.1;P<.0001)。
- 仅GEP高危者总生存短于两者均无者(HR=5.1;95%CI 2.4-11.1;P<.0001);仅IMS/IMWG高危者总生存短于两者均无者(HR=3.2;95%CI 1.6-6.2;P=.0007)。
关键数值与推荐
- 早期复发定义为自体干细胞移植后维持治疗随机化起<18个月内复发。
- 真正功能性高危需同时无IMS/IMWG高危细胞遗传学异常和GEP高危特征且无孤立高危标志。
临床怎么用
- 作者认为结果支持更全面的基线诊断分析以 upfront 识别早期复发风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Functional high-risk (FHR) multiple myeloma (MM) is defined as an unexpected, early relapse (ER) of disease in the absence of baseline molecular or clinical risk factors (RF), making FHR MM inherently dependent on which RFs were assessed at diagnosis, and what treatment patients received. To establish the true incidence of FHR, we analyzed uniformly treated, transplant-eligible patients from the Myeloma-XI (MyXI) trial that had been profiled for the International Myeloma Society and Working Group (IMS/IMWG) defined high-risk cytogenetic aberrations (HRCA), and the SKY92 gene expression HR signature (GEP-HR). A total of 135 MyXI patients were studied, with a median follow-up of 88 months; 25 (18.5%) experienced ER, defined as relapse <18 months from maintenance randomization post-autologous stem-cell transplantation. Hereof, 15 (60%) were IMS/IMWG-HR at diagnosis, of whom 8 were also GEP-HR. Another 6 patients were GEP-HR only and would have been missed by IMS/IMWG-HR. Among 4 patients with IMS/IMWG- and GEP-standard risk, 2 had isolated HR markers at diagnosis, leaving only 2 patients (8% of ER; 1.5% of all) truly meeting all FHR-criteria. Combined IMS/IMWG-HR and GEP-HR profiling identified 84% of ER, and differentiated long-term outcome across all 135 patients: co-occurring IMS/IMWG and GEP-HR was associated with very short overall survival compared to the absence of both (HR = 13.1; 95% CI, 6.5-26.1, P < .0001), followed by GEP-HR only (HR = 5.1; 95% CI, 2.4-11.1, P < .0001) and IMS/IMWG-HR only (HR = 3.2; 95% CI, 1.6-6.2, P = .0007). Our results support more comprehensive baseline diagnostic profiling to identify those at risk of ER upfront. The trials were registered at the ISRCTN Registry as ISRCTN49407852 and at clinicaltrials.gov as #NCT01554852.
引用
- Beer SA, Cairns DA, Pawlyn C, et al. Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling. Blood. 2025. PMID: 40834881. doi:10.1182/blood.2025029987
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。